Navigation Links
SpectraCell Now Offers LPP™ Cardiovascular Testing in New York
Date:4/28/2011

HOUSTON, April 28, 2011 /PRNewswire/ -- SpectraCell Laboratories has officially been granted a license to provide its Lipoprotein Particle Profile™ (LPP™) test, which assesses cardiovascular risk, to New York state physicians and patients.  The recently patented LPP™ test has been commercially available to the other 49 states since 2006.

SpectraCell began the process of acquiring a licensure in 2008 with an application submission to the state of New York.  The laboratory underwent an initial inspection by the New York State Department of Health in late 2009 followed by extensive documentation validating the LPP™ procedure, which is standard protocol required of all diagnostic laboratories.  A final inspection in December 2010 concluded the evidentiary process, proving the LPP™ technology is valid, accurate and reproducible.

"Acquiring our New York license allows us to serve the largest metropolitan area in the country," states Dr. Fred Crawford, Ph.D., VP of Operations and Laboratory Director at SpectraCell Labs. "In fact, many physicians in the state of New York have wanted to implement the LPP™ test in their practice but were unable to do so until now.  Plus, we recently streamlined our LPP™ report using feedback from existing LPP™ clients, making it easier than ever for physicians to translate LPP™ results into clinical decisions."

New York represents a large market for laboratory testing.  According to a CNN report, approximately 40,000 physicians practice within a 30 mile radius of New York City, in contrast to a national average of about 8000 physicians for other American cities.

After visiting the laboratory and reviewing the testing protocol, Dr. Robert Rej, Director of Chemistry for the State of New York Department of Health recommended the permit be approved for SpectraCell's LPP™ testing. The license also allows SpectraCell to add FDA approved chemistry procedures to New York clients.  Their first addition will be LpPLA2 testing (lipoprotein-associated phospholipase A2) which measures a specific enzyme linked to thrombosis (blood clots), indicating a higher risk of heart attack or stroke.  

Just a few months ago, SpectraCell Laboratories was awarded a patent on their Lipoprotein Particle Profile™ (LPP™) test, which measures both the size and number of lipoproteins rather than the cholesterol contained within them.  In recent years, more doctors have seen standard cholesterol tests label a patient "normal" when in reality their risk for heart disease is quite high.

In fact, The National Cholesterol Education Program (NCEP) acknowledges that 50% of people that have heart attacks have "normal" cholesterol – that is, cholesterol below 200 mg/dL.  The LPP™ test allows physicians to stratify risk more accurately, thus prescribing therapies that will be the most effective, depending on their patients' specific lipid profile.

NCEP recognizes four risk factors that are not measured with routine cholesterol testing but are all measured by the LPP™ test:

  1. RLP – (remnant lipoprotein) more easily converted into arterial plaque than other lipoproteins
  2. Lp(a) – a dangerous lipoprotein that contributes to clot formation
  3. HDL2b – a type of HDL that indicates how well cholesterol is being cleared from your system
  4. Small, dense LDL – easily penetrates vascular wall, causing damage and plaque

The LPP™ is part of the trend toward more individualized medicine. The LPP™ test, which is done on a fasting blood sample, is usually covered by insurance.  Results typically take 3-5 days. For more information, go to www.spectracell.com.

About SpectraCell Laboratories – SpectraCell is a CLIA accredited laboratory that services healthcare providers nationwide by providing advanced clinical testing such as micronutrient testing, telomere analysis, Omega 3 Index and the Lipoprotein Particle Profile™ (LPP™).

SpectraCell's Lipoprotein Particle Profile™ is the most advanced lipoprotein test available. Unlike traditional cholesterol tests, SpectraCell's LPP™ directly measures both the size (density) and number of several classes of lipoprotein particles providing an accurate assessment of cardiovascular risk.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Dr. Fred Crawford, Ph.D.

http://www.profnetconnect.com/drj_fredcrawfordphd


'/>"/>
SOURCE SpectraCell Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. SpectraCell Contracts With Beech Street Corporation
2. SCAN Health Plan Offers Seniors Five Tips to Prepare for Surgery
3. BioInformatics, LLC Offers Solutions for Optimizing Service and/or Maintenance Contracts
4. Minnesota Chiropractic Association Offers Backpack Safety Checklist
5. Spherics, Inc. Offers Once Daily Extended Release Formulation for Sustained and Stable Pramipexole Delivery
6. GlaxoSmithKline Offers New Purchasing Options to Help Employers Overcome Barriers to Pandemic Stockpiling of Relenza(R)
7. Orange Coast Urology Offers Advanced In-Office Patient EVOLVE(R) Laser Prostate Treatment
8. Friends of the Earth Report on Biofuel Production Offers Incomplete, Outdated and Inaccurate Picture, According to Brazilian Sugarcane Industry Association
9. ProSource 2.0 Offers Value, Savings for Lab Supplies
10. KGI Offers Mammalian Cell Culture Program for Biotech Industry Professionals
11. LI-COR Biosciences Offers $1.75 Million in Matching Funds for Undergraduate Genomics Education
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... From wearable devices that can ... sports. On Thursday, December 15th a panel of entrepreneurs, innovators and a Philadelphia ... at a Smart Talk session. Smart Talk will run from 8:30 – 10:30 ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... to control cells — optogenetics — is key to exciting advances in the ... art, spatially patterned light projected via free-space optics stimulates small, transparent organisms and ...
(Date:12/8/2016)... ... December 08, 2016 , ... KBioBox llc announced today ... demand KbioBox developed a sophisticated “3 click” gene dditing off target analysis program ... new website, https://www.kbiobox.com/ and powered by the company’s proprietary BioEngine. ...
(Date:12/8/2016)... 8, 2016 Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... developing and commercializing products to treat rare diseases where ... it will be hosting an Investor Webcast Event Friday, ... origins of innate defense regulators (IDRs) as a new ... mucositis and the recently announced and published Phase 2 ...
Breaking Biology Technology:
(Date:11/15/2016)... , Nov 15, 2016 Research and ... Global Forecast to 2021" report to their offering. ... ... USD 16.18 Billion by 2021 from USD 6.21 Billion in 2016, ... Growth of the bioinformatics market is driven by the ...
(Date:6/22/2016)... 22, 2016  The American College of Medical Genetics and ... Magazine as one of the fastest-growing trade shows during ... the Bellagio in Las Vegas . ... of growth in each of the following categories: net square ... number of attendees. The 2015 ACMG Annual Meeting was ranked ...
(Date:6/20/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring announced that ... has secured the final acceptance by all three ... Access Systems (MAS) installed. Furthermore, Securus will have ... installed by October, 2016. MAS distinguishes between legitimate ...
Breaking Biology News(10 mins):